Recursion Pharmaceuticals (RXRX) Total Debt Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 5.94% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 103.99% |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.07% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.90 Bn | 1.24 Bn | -6.02 Mn | -34.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.30% |
| Dec 31, 2025 | -32.03% |
| Sep 30, 2025 | -27.53% |
| Jun 30, 2025 | -26.05% |
| Mar 31, 2025 | 2,237.35% |
| Dec 31, 2024 | 2,303.42% |
| Sep 30, 2024 | 2,451.42% |
| Jun 30, 2024 | 2,586.58% |
| Mar 31, 2024 | -9.16% |
| Dec 31, 2023 | 113.06% |
| Sep 30, 2023 | 100.71% |
| Jun 30, 2023 | 97.10% |
| Mar 31, 2023 | 93.28% |
| Dec 31, 2022 | -15.32% |
| Sep 30, 2022 | -14.48% |
| Jun 30, 2022 | -93.78% |
| Mar 31, 2022 | -94.10% |
| Dec 31, 2021 | -94.45% |